HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib.

Abstract
The HIV protease inhibitor nelfinavir is an investigational drug for cancer treatment. We have previously demonstrated induction of apoptosis by nelfinavir even in chemo-resistant ovarian cancer cells. In contrast to the pro-apoptotic effect of nelfinavir on human cancer cells, we noticed a significant upregulation of the anti-apoptotic mitochondrial membrane protein mcl-1 by nelfinavir, resulting in a mitochondria-independent induction of apoptosis. Upregulation of mcl-1 was associated with enhanced phosphorylation of both mcl-1 and of ERK1/2 (extracellular signal-regulated kinases 1/2). ERK1/2 enhanced stability of mcl-1 protein expression by serine-163 phosphorylation. The combination of nelfinavir with sorafenib, a clinically applied inhibitor of the RAS/RAF/ERK1/2 pathway, inhibited nelfinavir-induced ERK1/2 activation and mcl-1 protein upregulation. Further, the combination of nelfinavir with sorafenib induced mitochondrial membrane potential disruption and resulted in an improved activity of nelfinavir on ovarian cancer cells. Thus, a combination of these two investigational anti-cancer drugs could be of interest especially because of their unique mechanism of apoptosis induction even in otherwise chemo-resistant human cancer cells.
AuthorsAnsgar Brüning, Petra Burger, Marianne Vogel, Andrea Gingelmaier, Klaus Friese, Alexander Burges
JournalInvestigational new drugs (Invest New Drugs) Vol. 28 Issue 5 Pg. 535-42 (Oct 2010) ISSN: 1573-0646 [Electronic] United States
PMID19554262 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Annexin A5
  • Antineoplastic Agents
  • Benzenesulfonates
  • HIV Protease Inhibitors
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Phenylurea Compounds
  • Proto-Oncogene Proteins c-bcl-2
  • Pyridines
  • Niacinamide
  • Propidium
  • Sorafenib
  • Extracellular Signal-Regulated MAP Kinases
  • Nelfinavir
Topics
  • Annexin A5 (metabolism)
  • Antineoplastic Agents (pharmacology)
  • Benzenesulfonates (pharmacology)
  • Cell Death (drug effects)
  • Cell Line, Tumor
  • Drug Synergism
  • Extracellular Signal-Regulated MAP Kinases (metabolism)
  • Female
  • HIV Protease Inhibitors (pharmacology)
  • Humans
  • Membrane Potential, Mitochondrial (drug effects)
  • Mitochondria (drug effects, metabolism)
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Nelfinavir (pharmacology)
  • Niacinamide (analogs & derivatives)
  • Ovarian Neoplasms (enzymology, pathology)
  • Phenylurea Compounds
  • Phosphorylation (drug effects)
  • Propidium (metabolism)
  • Protein Stability (drug effects)
  • Proto-Oncogene Proteins c-bcl-2 (metabolism)
  • Pyridines (pharmacology)
  • Sorafenib

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: